The law firm of Meyerson & Miller is currently investigating a possible increased risk of cardiovascular events in patients utilizing an inhaler to control chronic obstructive pulmonary disease (COPD), which contains the active ingredient ipratropium bromide, such as Atrovent.
Researchers from the University of Washington and Hines VA Hospital have conducted a cohort study on United States veterans between 1999 and 2002 who were using medications containing ipratropium bromide. Results showed that any exposure to medications within six months of use was associated with an increased risk of cardiovascular events. Researches noted that their findings were consistent with previous concerns raised in the medical community about the cardiovascular safety of ipratropium bromide.
If you or a loved one has suffered a cardiovascular injury or death while utilizing an inhaler containing ipratropium bromide, such as Atrovent, you may be entitled to monetary compensation for your injuries. If you would like to have an attorney contact you for a free and confidential consultation contact us.
If you or a loved one has suffered a cardiovascular injury or death while utilizing an inhaler containing ipratropium bromide, such as Atrovent, you may be entitled to monetary compensation for your injuries.
If you would like to have an Atrovent Inhaler attorney contact you for a free and confidential consultation, please
contact us.